Simpson Thacher Adds Leading Private Equity Lawyer James Howe
Simpson Thacher & Bartlett LLP announced today that James Howe has joined its Mergers and Acquisitions Practice as a Partner in the London office.
“We are very pleased to welcome James to Simpson Thacher,” said Bill Dougherty, Chairman of Simpson Thacher’s Executive Committee. “His extensive experience advising private equity firms and financial institutions on complex deals in the United Kingdom, continental Europe and around the world will further enhance our strong London-based platform.”
James is a rising star in private equity M&A who focuses on cross-border leveraged buyouts, mergers and acquisitions and corporate finance transactions. He has advised a wide range of clients across the globe, including many of the world’s leading private equity sponsors and financial institutions. He joins the Firm from Gibson, Dunn & Crutcher LLP.
“Given his experience advising many of the most sophisticated private equity sponsors on a wide range of high-profile transactions, James is a perfect fit for the Firm,” said Jason Glover, Managing Partner of the London Office. “His dealmaking prowess further bolsters our existing top-notch global private equity mergers and acquisitions capabilities, adding further depth to our extraordinarily talented bench of lawyers in London.”
“James has earned an excellent reputation in the market for his commercial nature and ability to provide clients with well-rounded advice that is solutions-driven. He is a wonderful addition to the team and we are thrilled to welcome him to our Mergers and Acquisitions Practice in London,” said London Mergers and Acquisitions Head, Ben Spiers.
Simpson Thacher is consistently ranked among the world’s leading mergers and acquisitions advisors, offering clients the skill and insight gained by representing M&A players globally in virtually all capacities under U.S., English and Hong Kong law. The Firm’s M&A attorneys are regularly retained in all types of negotiated transactions, including mergers, stock and asset purchases, restructurings, spin-offs, joint ventures, minority investments and private equity transactions, as well as contested acquisitions and proxy fights.
“Simpson Thacher is a global leader in mergers and acquisitions and the private equity sector. I look forward to working with the distinguished team in London and around the world to continue providing clients with innovative solutions and best-in-class advice to help them achieve their commercial goals,” James said.
ABOUT SIMPSON THACHER
Simpson Thacher & Bartlett LLP (www.simpsonthacher.com) is one of the world’s leading international law firms. The Firm was established in 1884 and has more than 1,000 lawyers. Headquartered in New York with offices in Beijing, Hong Kong, Houston, London, Los Angeles, Palo Alto, São Paulo, Tokyo and Washington, D.C., the Firm provides coordinated legal advice and transactional capability to clients around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005236/en/
Contact information
Caroline Fatchett
mediainquiries@stblaw.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv811.12.2025 15:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chronic mechanical low back pain associated with multifidus muscle dysfunction. ReActiv8® restorative neurostimulation is the only therapy approved in the United States, Europe and Australia for this indication. The Statement, which affirms ISASS’ support for coverage by payers of implantable restorative neurostimulation in appropriately selected patients, was published in the December issue of the International Journal of Spine Surgery and can be accessed here: https://www.ijssurgery.com/content/early/2025/12/10/8833. The Statement reflects the growing body of clinical evidence supporting the use of ReActiv8, as well as recent developments in diagnostic coding and reimbursement pathways since ISASS’ 2023 Statement on Restorative Neurostimulation for Chr
SLB Enters Collaboration Agreement to Accelerate New Digital Solutions11.12.2025 15:28:00 EET | Press release
Global energy technology company SLB (NYSE: SLB) signed a strategic collaboration agreement with Shell to develop digital and AI solutions that drive measurable performance and efficiency gains across upstream operations for the company and the wider industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211832051/en/ The collaboration has the ambition to develop agentic AI-powered solutions that will accelerate and amplify the capabilities of technical experts and decision makers. The aim is to develop and deploy an open data and AI infrastructure that unifies data and workflows across subsurface, well construction and production in a secure digital environment, using SLB’s Lumi™ data and AI platform. The collaboration has the ambition to develop agentic AI-powered solutions that will accelerate and amplify the capabilities of technical experts and decision makers. The aim is to develop and deploy an open data and AI i
Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas11.12.2025 15:00:00 EET | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcoming 300M cell project. Tahoe will use its proprietary Mosaic technology to generate samples consisting of 300M cells from large arrays of disease models, genetically or chemically perturbed. Under this agreement, Parse will apply its Evercode™ chemistry and high-throughput automation to these samples to deliver the largest perturbation-focused single cell dataset ever produced. Parse’s GigaLab, designed specifically for million- to hundred-million-cell projects, has rapidly become an industry benchmark for large-scale, reproducible single cell data generation. The facility integrates high-capacity liquid handling, standardized workflows, and end-to-end QC to enable dataset sizes previously unattainable for most research organizations. The Tahoe project represents one of the largest sequencin
Xsight Labs X2 Switch to Enable Next-Generation Starlink Satellites and Deliver Gigabit Connectivity11.12.2025 15:00:00 EET | Press release
Xsight Labs, an innovator in high-performance connectivity silicon, today announced that Starlink, the world’s most advanced satellite constellation in low-Earth orbit, delivering broadband, will leverage the Xsight X2 Programmable Ethernet switch to serve as the high-speed networking core for its next-generation Starlink V3 satellites. Each V3 Starlink satellite is designed to deliver more than 1 terabit per second (Tbps) of fronthaul throughput, more than 10× the capacity delivered by Starlink V2 Mini satellites, and about 160 gigabits per second (Gbps) of uplink capacity. Starlink’s global broadband service depends on processing and routing large volumes of real-time data, including inter-satellite optical link traffic, orbital mesh routing decisions, adaptive beam steering, and the high-throughput downlink required to serve its customers. The X2 delivers 12.8 Tbps of switching capacity using state-of-the-art 100G SerDes and TSMC’s N5 process, providing a power-efficient, ultra-low-
Payments Leaders Unprepared for 2026 Disruption, Warns ACI Worldwide11.12.2025 14:36:00 EET | Press release
Most global payments leaders lack a clear roadmap to navigate the seismic changes coming in 2026 , according to the latest Top Ten Payments Predictions from ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology. With AI-driven intelligence, next-gen authentication, new regulatory frameworks, and soaring demand for instant, embedded, and secure payments, the industry is entering an era of structural disruption. However, ACI’s recent report Payments in Transition: Leadership in an era of transformation reveals that only 36% of payments executives have a clear long-term modernization roadmap, leaving many without a strategic vision for transformation. “In 2026, payments disruption won’t be incremental—it will be structural,” said Philip Bruno, Chief Strategy and Growth Officer at ACI Worldwide. “Real-time is now the baseline, digital assets are entering regulated ecosystems, and AI is transforming every layer of the value chain. Our research is a clear warning:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom